Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA;Aktueller stand der MRT-diagnostik mit leberspezifischen kontrastmitteln: Gd-EOB-DTPA und Gd-BOPTA

Radiologe

Volumn 44, Issue 12, 2004, Pages 1185-1191

  Stroszczynski, C ^a   Gaffke, G ^a   Gnauck, M ^a   Streitparth, F ^a   Wieners, G ^a   Lopez Haninnen E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gd BOPTA; Gd EOB DTPA; Liver specific contrast agents; MRI diagnostics

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOLINIUM CHELATE; GADOXETIC ACID;

BOLUS INJECTION; COMPUTER ASSISTED TOMOGRAPHY; DRUG SPECIFICITY; HEPATOBILIARY SYSTEM; HUMAN; INTERMETHOD COMPARISON; LIVER DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; VASCULARIZATION;

CHELATING AGENTS; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PHYSICIAN'S PRACTICE PATTERNS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 12344321314     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-004-1134-5     Document Type: Review

References (31)

1. Bollow M, Taupitz M, Hamm B, Staks T, Wolf KJ, Weinmann HJ (1997) Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Eur Radiol 7 (1):126-132
2. Carlos RC, Branam JD, Dong Q, Hussain HK, Francis IR (2002) Biliary imaging with Gd-EOB-DTPA: is a 20-minute delay sufficient? Acad Radiol 9 (11):1322-1325
3. Del Frate C, Bazzocchi M, Mortele M et al. (2002) Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology 225 (3):766-772
4. De Haen C, Gozzini L (1993) Soluble-type hepatobiliary contrast agents for MR imaging. J Magn Reson Imaging 3:179-186
5. Fujita M, Yamamoto R, Takahashi M et al. (1997) Paradoxic uptake of Gd-EOB-DTPA by hepatocellular carcinoma in mice: quantitative image analysis. J Magn Reson Imaging 7 (4):768-770
6. Grazioli L, Morana G, Kirchin MA (2003) MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison. J Magn Reson Imaging 17 (5):593-602
7. Helmberger T, Holzknecht N, Schopf U (2001) Radiofrequenzablation von Lebermetastasen. Technik und erste Ergebnisse. Radiologe 41 (1):69-76
8. Hirohashi S, Hirohashi R, Uchida H et al. (1998) Optimal dose of hepatobiliary contrast agent for MR cholangiography: experimental study in rats. J Magn Reson Imaging 8 (4):847-852
9. Huppertz A, Balzer T, Blakeborough A (2004) Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230 (1):266-275
10. Kim MJ, Kim JH, Chung JJ, Park MS, Lim JS, Oh YT (2003) Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology 228 (3):719-726
11. Kim YK, Kim CS, Lee YH, Kwak HS, Lee JM (2004) Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas. AJR Am J Roentgenol 182 (5):1217-1223
12. Kirchin MA, Pirovano G, Venetianer C, Spinazzi A (2001) Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 14:281-294
13. Kumano S, Murakami T, Kim T (2003) Using superparamagnetic iron oxide-enhanced MRI to differentiate metastatic hepatic tumors and nonsolid benign lesions. AJR Am J Roentgenol 181 (5):1335-1339
14. Kuwatsuru R, Kadoya M, Ohtomo K (2001) Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol 36 (11):632-641
15. Marchal G, Zhang X, Ni Y, Van Hecke P, Yu J, Baert AL (1993) Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: a correlation study of MR imaging, microangiography, and histology. Magn Reson Imaging 11:665-674
16. Ni Y et al. (1994) MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings. Radiology 190:753-758
17. Petersein J, Spinazzi A, Giovagnoni A et al. (2000) Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging - a multicenter phase III clinical study. Radiology 215 (3):727-736
18. Pirovano G, Vanzulli A, Marti-Bonmati L et al. (2000) Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. Am J Roentgenol 175 (4):1111-1120
19. Reimer P, Tombach B, Daldrup H et al. (1996) Neue MRT-Kontrastmittel für die Leberdiagnostik. Radiologe 36 (2):124-133
20. Reimer P, Rummeny EJ, Shamsi K et al. (1996) Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 199 (1):177-183
21. Runge VM (1998) A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. J Comput Assist Tomogr 22 (4):643-650
22. Schneider G, Maas R, Schultze Kool L (2003) Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 38 (2):85-94
23. Spinazzi A et al. (1999) Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 6:282-291
24. Stern W, Schick F, Kopp AF et al. (2000) Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 41 (3):255-262
25. Stroszczynski C, Gaffke G, Gnauck M et al. (2004) Aktueller Stand und neue Entwicklungen der Laserablation in der Tumortherapie. Radiologe 44 (4):320-329
26. Tanimoto A, Satoh Y, Yuasa Y, Jinzaki M, Hiramatsu K (1997) Performance of Gd-EOB-DTPA and superparamagnetic iron oxide particles in the detection of primary liver cancer: a comparative study by alternative free-response receiver operating characteristic analysis. J Magn Reson Imaging 7 (1):120-124
27. Tsuda N, Kato N, Murayama C, Narazaki M, Yokawa T (2004) Potential for differential diagnosis with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in experimental hepatic tumors. Invest Radiol 39 (2):80-88
28. Vogl TJ, Kummel S, Hammerstingl R (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200 (1):59-67
29. Ward J, Guthrie JA, Scott DJ (2000) Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 216 (1):154-162
30. Yoshikawa K, Inoue Y, Shimada M (2004) Contrast-enhanced MR angiography in rats with hepatobiliary contrast agents. Magn Reson Imaging 22 (7):937-942
31. Youk JH, Lee JM, Kim CS (2004) MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents. AJR Am J Roentgenol 183 (4):1049-1054